Live
- ‘Pushpa-2’ row: Celebs & politicos fail to act fairly
- Learn from fighting spirit of women bravehearts: VHP VP
- BJP MP Arvind, MLA Sanjay Kumar meet CM Revanth
- Rapido partners with L&TMRHL to provide discounted rates
- Kisan Diwas 2024: A Day Dedicated to honor our Farmers.
- Axed ACP takes the wind out of Pushpa hero’s sails
- Tender apology to CM, mantri tells Allu Arjun
- CM condemns attack on Allu Arjun’s house
- Allu Arjun’s house attacked, police arrest 6 persons in city
- APSRTC to replace diesel buses with electric buses
Lupin launches Doxercalciferol drug in US
Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
New Delhi: Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
The company has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, after having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The product is a generic version of Sanofi Genzyme's Hectorol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, it added.
According to the IQVIA MAT October 2019 data, Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials had an annual sales of around $132 million in the US, Lupin said.
"It is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis," it added.
